Jay Rosanelli is the CEO and Co-Founder of Syenex, a biotech developing a platform for in vivo gene therapy delivery. While capital in the gene and cell therapy (CGT) space has grown over the last 5 years, there remain serious bottlenecks in delivery. In this conversation, we discuss what Syenex is building, the future of CGT, and what's next in AI-driven drug discovery and neurotech. Check out what Syenex is building: https://www.syenex.com/ 0:00 Introduction 0:55 Background 4:56 Biotech Capital 11:50 The Delivery Problem 17:37 Platform vs. Therapeutics 24:08 Partnership Model31:28 In-vivo CAR-T 37:49 Economics of Platform 42:08 AI x BIo 48:19 Future of BiotechABOUT MEHi, my name is Shriya; I'm a sophomore at Harvard and the host of the Bio/Acc Podcast. I started this podcast out of the Harvard Bioethics Communication Initiative to conduct deeply researched interviews with the world's most interesting people in biotech.Produced by ‪@RishabJainSOCIAL LINKS:🎤 Listen on Spotify: https://open.spotify.com/episode/4m42...🎤 Listen on Apple: https://podcasts.apple.com/us/podcast...See our Website: https://bioacceleration.com/Connect w/ Shriya on Linkedin: www.linkedin.com/in/shriya-bhat-0b845b203Let us know what you think in the comments below! Subscribe to our channel for more podcasts.